Skip to main content
Swing Capital

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB BSE: 532305

Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]

₹132
52W: ₹70.7 — ₹157
PE 25.6 · Book ₹159 · -17% vs book
Market Cap₹1,144 Cr
Stock P/E25.6Price to Earnings
ROCE1.37%Return on Capital
ROE0.82%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Stock is trading at 0.81 times its book value
  • +Company has delivered good profit growth of 19.0% CAGR over last 5 years
  • +Promoter holding has increased by 3.49% over last quarter.

Weaknesses

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of -6.07% over past five years.
  • −Company has a low return on equity of 8.86% over last 3 years.
  • −Earnings include an other income of Rs.274 Cr.

Shareholding Pattern

Promoters43%
FIIs13.88%
DIIs0%
Public43.14%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters42.01%42.01%42.01%40.94%▼1.140.94%39.49%▼1.439.49%43%▲3.5
FIIs1.27%0.65%▼0.60.46%▼0.23.07%▲2.64.27%▲1.214.8%▲10.514.33%▼0.513.88%▼0.4
DIIs0.94%0.94%0.94%0.91%▼0.00.91%0.68%▼0.20.68%0%▼0.7
Public55.81%56.41%▲0.656.61%▲0.255.08%▼1.553.88%▼1.245.02%▼8.945.5%▲0.543.14%▼2.4

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales270276517303122145148150149
Expenses2072224303515122158145148144
Operating Profit635487-5-12-1-13325
OPM %23%20%17%-15%-443%-1%-9%2%1%4%
Net Profit302249160-12188911
EPS ₹5.093.6683.051.050.05-0.1535.981.341.071.32

AI Insights

Revenue Trend

TTM revenue at ₹593Cr, up 7.8% YoY. OPM at 0%.

Debt Position

Borrowings at ₹22Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.

Institutional Flow

DIIs: 0% (-19.49pp change). FIIs: 13.88% (+13.80pp change). Promoters hold 43%.

Margin & Efficiency

ROCE improving from 0% (Mar 2014) to 1% (Mar 2025). Working capital days: 83.

Valuation

PE 25.6x with 1.37% ROCE. Price is -17% above book value of ₹159. Dividend yield: 0%.

Recent Announcements